- Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.
- Eli Lilly and Novo Nordisk both launched oral GLP-1 medications this year, marking a major competitive development in the market.
- Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.
Teva obtained FDA approval for a generic drug, challenging Novo Nordisk's market share in the GLP-1RA space.
2 reports, 2 independent
Updated Aug 30
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Teva obtained FDA approval for a generic drug, challenging Novo Nordisk's market share in the GLP-1RA space.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.Also in this story
- Novo Nordisk and Eli Lilly are utilizing physician networks in Texas, including Carlos Campos, to promote their weight-loss drugs.
- UK MHRA approved Foundayo for commercialization, marking a significant market entry point in the global obesity drug competition.
- Bullish outlook for Eli Lilly due to strong sales momentum and durable patent coverage for its obesity treatment portfolio into the 2030s.
- Eli Lilly and Novo Nordisk are leading the weight management market, with plans to seek label expansion applications in Europe.
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
Novo Nordisk
Danish pharmaceutical company
-
Teva Pharmaceutical Industries Ltd.
Israeli pharmaceutical company
Related events
- Teva's acquired product is currently undergoing review by the FDA.
- Eli Lilly referred entities to the FDA regarding the GLP-1 market on August 24, 2026.
- Eli Lilly and Novo Nordisk products are currently awaiting necessary approval from the Food and Drug Administration.
- Teva Pharmaceutical Industries Ltd. submitted an NDA for ecopipam to the FDA.
- Eli Lilly and Company received full FDA approval, expanded a safety study into India, and broke ground on a new facility in Houston while competing in the GLP-1 market.
Coverage
Newest first; wire copies grouped- Pharmaceutical TechnologyTeva brings first generic GLP-1 to US market with Saxenda copycat approval Generics company Teva Pharmaceutical has obtained approval from the US Food and Drug Administration (FDA) for its generic re
- Pharma VoiceDespite FDA ruling, compounded GLP-1s are still giving Novo and Lilly headaches on the market This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our